Gonadotropin releasing hormone transdermal patch - Vyteris

Drug Profile

Gonadotropin releasing hormone transdermal patch - Vyteris

Alternative Names: Fertility hormone peptide Smart Patch™ transdermal patch; GnRH transdermal patch - Vyteris

Latest Information Update: 06 Jun 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vyteris
  • Class Gonadotropins; Hormones; Infertility therapies
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Female infertility

Most Recent Events

  • 06 Jun 2013 Vyteris plans to sell transdermal drug delivery patents, subject to approval of US Bankruptcy Court
  • 06 Jun 2013 No development reported - Phase-II for Female infertility in USA (Transdermal)
  • 10 Nov 2010 Vyteris receives a grant under the US Government's Qualifying Therapeutics Discovery Project for the development of Smart Patch-based therapeutics in female infertility and diabetes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top